A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.
Completed
Phase 2
| Drug | Synonyms | Arms |
|---|---|---|
| Pemetrexed | Arm 1 Pem, carbo, placebo x 4 cycles | |
| Carboplatin | Arm 1 Pem, carbo, placebo x 4 cycles | |
| demcizumab | Arm 2 Pem, carbo x 4 cycles, one course of dem |
Patients will be enrolled at centers in North America, Western Europe, Australia and New
Zealand. Up to 28 days (4 weeks) prior to treatment.
If enrolled in the study, you will receive intravenous (in the vein) infusions of demcizumab
(or placebo), carboplatin, and pemetrexed administered on the same day, every 21 days for 4
cycles, or until it has been shown that your cancer has gotten worse. If your physician
decides to delay treatment with one of the agents due to side effects, the other agents may
still be administered as scheduled. After 4 cycles, if you have stable or improved disease,
you will continue to receive pemetrexed once every 21 days as maintenance therapy. After 8
cycles, if you have stable or improved disease, you may receive demcizumab (or placebo),
every 21 days for 4 more cycles.
You will undergo assessments every 6 weeks to determine the status of your disease.
| Name | Type | Description | Interventions |
|---|---|---|---|
| Arm 1 Pem, carbo, placebo x 4 cycles | Placebo Comparator | Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84 |
|
| Arm 2 Pem, carbo x 4 cycles, one course of dem | Active Comparator | Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84 |
|
| Arm 3 pem, carbo, dem x 4 cycles, dem retreatment | Active Comparator | Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg |
|
Main Inclusion Criteria:
1. Signed Informed Consent Form
2. Histologically or cytologically confirmed Stage IV non-squamous NSCLC
3. Availability of FFPE (formalin-fixed paraffin-embedded) tumor tissue, either fresh
core-needle-biopsied or archived
4. Age > or = to 21 years
5. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1
6. Disease that is measurable per RECIST v1.1
7. Adequate organ and marrow function
8. For women of childbearing potential, agreement to use two effective forms of
contraception
Main Exclusion Criteria:
1. Histologically or cytologically documented, advanced, mixed non-small cell and small
cell tumors or mixed adenosquamous carcinomas
2. NSCLC with known EGFR (epidermal growth factor receptor ) mutation or anaplastic
lymphoma kinase (ALK) gene translocation (such as EML4 [echinoderm
microtubule-associated protein-like 4]-ALK [anaplastic lymphoma kinase])
3. Prior or ongoing therapy (including chemotherapy, antibody therapy, tyrosine kinase
inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational therapy)
for the treatment of Stage IV non-squamous NSCLC
4. Evidence of tumor invading major blood vessels, cavitation of one or more pulmonary
tumor mass(es) or tracheo-esophageal fistula
5. Brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active
neurologic disease
6. Malignancies other than non-squamous NSCLC successfully treated within 3 years prior
to randomization (with the exception of certain early-stage cancers)
7. History of a significant allergic reaction attributed to humanized or human monoclonal
antibody therapy
8. Significant intercurrent illness defined as an illness that may result in the
subject's death prior to their death from non-squamous NSCLC and/or significantly
limit their ability to comply with the requirements of this study
9. Recent hemoptysis >2.5 mL or serious bleeding from another site, known bleeding
disorder or coagulopathy or therapeutic anti-coagulation
10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to randomization, or anticipation of need for major surgical procedure during
the course of the study
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 21 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
| Measure: | To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. |
| Time Frame: | Response assessment data was collected until the subject started alternative anti-cancer treatment or developed progressive disease, whichever occurred first, assessed up to approximately 26 months. |
| Safety Issue: | |
| Description: | Investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 response rate (unconfirmed) in placebo/placebo arm to demcizumab/placebo arm and demcizumab/demcizumab arm combined in subjects with first-line stage IV non-small cell lung cancer (NSCLC). Response rate was based on Investigator-assessed best-overall-response (BOR) and was defined as the best unconfirmed response determined by RECIST version 1.1 recorded from the start of the treatment until disease progression in the following order of importance: CR, PR , SD, progressive disease (PD), not evaluable, or missing. |
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Completed |
| Lead Sponsor: | OncoMed Pharmaceuticals, Inc. |
September 9, 2020
